Managing Neonatal Abstinence Syndrome: Screening and Medication Monitoring

Neonatal abstinence syndrome (NAS) affects infants who were exposed to opioids or other substances while in the womb.1 NAS has become more common in recent…

Novel Psychoactive Substances: Newly Identified Threats Detected in the Second Half of 2022

Novel Psychoactive Substances (NPS) are a diverse group of synthetic substances created to mimic the effects of scheduled or illicit drugs. There are various…

Impacts of Bariatric Surgery

Bariatric Surgeries1,2,6 Restrictive procedures Sleeve gastrectomy Gastric banding Vertical banded gastroplasty Malabsorptive procedures –…

Novel Psychoactive Substances: What is Xylazine?

Substance use can take many forms and often involves many unknowns. One of the most important aspects of illicit substance use, especially for the end…

Medication Monitoring in a Changing Opioid Prescribing Landscape

The new 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain is an update to the most recent practice guideline published in 2016.1,2…

Aegis's Novel Psychoactive Substance (NPS) Testing Menu Update

In September, Aegis updated both urine and oral fluid novel psychoactive substance (NPS) test menus as a continued commitment to offering providers a contemporary…

InterACT Rx Pharmacodynamic Insights: A Brief Look at QTc Prolongation, Serotonin Syndrome, and Tardive Dyskinesia

Introduction Some combinations of medications can lead to serious pharmacodynamic interactions with clinical effects that can be life-threatening in some…